Literature DB >> 12869459

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.

Eike Wrenger1, Regina Müller, Michael Moesenthin, Tobias Welte, Jürgen C Frölich, Klaus H Neumann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12869459      PMCID： PMC1126510          DOI： 10.1136/bmj.327.7407.147

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  17 in total

1.  Spironolactone and congestive heart-failure.

Authors:  B Georges; C Beguin; M Jadoul
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

Review 2.  ABC of heart failure. Acute and chronic management strategies.

Authors:  T Millane; G Jackson; C R Gibbs; G Y Lip
Journal:  BMJ       Date:  2000-02-26

Review 3.  Diuretic complications.

Authors:  A Greenberg
Journal:  Am J Med Sci       Date:  2000-01       Impact factor: 2.378

4.  Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.

Authors:  Chamberlain I Obialo; Elizabeth O Ofili; Tariq Mirza
Journal:  Am J Cardiol       Date:  2002-09-15       Impact factor: 2.778

5.  Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.

Authors:  Daniel A Blaustein; Krishnan Babu; Arpitha Reddy; Michael H Schwenk; Morrell M Avram
Journal:  Am J Cardiol       Date:  2002-09-15       Impact factor: 2.778

6.  Serious adverse events experienced by patients with chronic heart failure taking spironolactone.

Authors:  C Berry; J J McMurray
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

7.  Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.

Authors:  J Bauersachs; D Fraccarollo; G Ertl; N Gretz; M Wehling; M Christ
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  Elderly heart failure patients with drug-induced serious hyperkalemia.

Authors:  D Vanpee; C H Swine
Journal:  Aging (Milano)       Date:  2000-08

9.  Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.

Authors:  H Schepkens; R Vanholder; J M Billiouw; N Lameire
Journal:  Am J Med       Date:  2001-04-15       Impact factor: 4.965

10.  Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.

Authors:  Yuwen Hu; Jeffrey P Carpenter; Albert T Cheung
Journal:  Anesth Analg       Date:  2002-07       Impact factor: 5.108
View more
  24 in total

1.  Diabetes may be independent risk factor for hyperkalaemia.

Authors:  Paul R Jarman; Hugh M Mather
Journal:  BMJ       Date:  2003-10-04

2.  [Heart insufficiency: therapy with selective aldosterone antagonists. EPHESUS study].

Authors:  S Nitschmann
Journal:  Internist (Berl)       Date:  2004-04       Impact factor: 0.743

3.  Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.

Authors:  Miles D Witham; Neil D Gillespie; Allan D Struthers
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

4.  [Effects of the RALE study. Hyperkalemia following spironolactone treatment].

Authors:  E Erdmann
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

5.  Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.

Authors:  Jörg Indermitte; Sabine Burkolter; Jürgen Drewe; Stephan Krähenbühl; Kurt E Hersberger
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  The frequency of inappropriate tablet splitting in primary care.

Authors:  R Quinzler; C Gasse; A Schneider; P Kaufmann-Kolle; J Szecsenyi; W E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

7.  Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Alessandra Dei Cas; Robert J Mentz; Stephen J Greene; Sadiya Khan; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Marvin A Konstam; Michele Senni; Gregg C Fonarow; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2014-06-24       Impact factor: 2.778

8.  Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).

Authors:  Chakradhari Inampudi; Sridivya Parvataneni; Charity J Morgan; Prakash Deedwania; Gregg C Fonarow; Paul W Sanders; Sumanth D Prabhu; Javed Butler; Daniel E Forman; Wilbert S Aronow; Richard M Allman; Ali Ahmed
Journal:  Am J Cardiol       Date:  2014-04-18       Impact factor: 2.778

9.  Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study.

Authors:  Matthew A Weir; David N Juurlink; Tara Gomes; Muhammad Mamdani; Daniel G Hackam; Arsh K Jain; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

10.  Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

Authors:  L Magro; A Conforti; F Del Zotti; R Leone; M L Iorio; I Meneghelli; D Massignani; E Visonà; U Moretti
Journal:  Eur J Clin Pharmacol       Date:  2007-11-09       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.